Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992895 | 0.83 | IDO1 (0.41) | LMNACYP19A1CYP2C19IDO1 | |
| SCHEMBL28118365 | 0.81 | PTGER4 (0.45) | LMNACYP19A1CYP2C19HTR2AHTR2C | |
| SCHEMBL7292525 | 0.81 | PGR (0.42) | LMNAHTR2AHTR2CCSNK1D | |
| SCHEMBL7290105 | 0.80 | PGR (0.43) | LMNACSNK1D | |
| SCHEMBL7285807 | 0.78 | KDM4E (0.56) | LMNAHTR2C | |
| SCHEMBL16292269 | 0.77 | LMNA (0.39) | LMNACYP19A1CYP2C19ABCC2 | |
| SCHEMBL7281288 | 0.76 | KDM4E (0.44) | LMNA | |
| SCHEMBL27480265 | 0.76 | KDM4E (0.46) | LMNACYP19A1 | |
| SCHEMBL29650348 | 0.75 | NR3C1 (0.50) | CSNK1D | |
| SCHEMBL2851614 | 0.75 | NR3C1 (0.50) | CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MUTABILIS (FR) | 2019-05-28 | — | — | US | disclosed |
| EP-3110803-B1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-2913330-A1 | Condensed derivatives of imidazole useful as pharmaceuticals | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MSR1, IFNAR1, NOD2 | LMNA 2216/4885CYP19A1 1089/4885CYP2C19 174/4885 |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MSR1, IFNAR1, NOD2 | LMNA 2216/4885CYP19A1 1089/4885CYP2C19 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.